Facial Expression Awareness Training to Understand and Recognize Emotions
NCT07923370, Not applicable, Recruiting, Children's Hospital of Philadelphia
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Facial Expression Awareness Training to Understand and Recognize Emotions | ClinicalTrials.gov |
| NCT number | NCT07923370 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 40 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Children's Hospital of Philadelphia | ClinicalTrials.gov |
| Conditions | Survivors of Pediatric Brain Tumors, Pediatric Cancer | ClinicalTrials.gov |
| Interventions | FaceSay, SuccessMaker Reading | ClinicalTrials.gov |
| First posted | 2026-11-06 | ClinicalTrials.gov |
| Last updated | 2026-11-06 | ClinicalTrials.gov |
Registered outcomes 11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | FaceSay Feasibility and Acceptability: Enrollment Rates | Across recruitment outreach period, up to 5 no-response contacts | Survivors and families will demonstrate interest in FaceSay, as defined by at least 75% of those approached enrolling in the study. | ClinicalTrials.gov |
| Primary | FaceSay Feasibility and Acceptability: Training Completion Rate | Training completion will be tracked for each participant across 6 weeks. A final completion rate for each participant will be calculated at the end of the 6-week period. | FaceSay will be feasible, as defined by 75% of randomized participants achieving over 80% treatment adherence (i.e., 10 of 12 training sessions over a 6-week period). | ClinicalTrials.gov |
| Primary | FaceSay Feasibility and Acceptability: Intervention Acceptability | Parent reports of the intervention across their 6-week training period will be assessed at their T2 follow-up visit. | FaceSay will be acceptable, as defined by family reports of ease-of-use and satisfaction. | ClinicalTrials.gov |
| Secondary | FaceSay Efficacy: Facial Identity Recognition Improvement | Enrollment to T3 (18 weeks) | At each time point, participants will be asked to complete the Victoria/Yale face processing assessment, which tests facial identity recognition skills. Overall accuracy scores (ranging from 0-100) for the facial identity recognition task will be used to quantify these skills, with higher scores reflecting better facial identity recognition. | ClinicalTrials.gov |
| Secondary | FaceSay Efficacy: Social Attention Improvement | Enrollment to T3 (18 weeks) | At each time point, participants doing in-person visits will complete a social attention paradigm that uses eye-tracking technology to capture the child's attention during a video of children playing. This task measures eye gaze during thirty-two 15-second videos depicting pairs of siblings engaging in either joint, cooperative or separate, parallel play. A Social Prioritization score will be calculated by subtracting the proportion of fixation time for background objects from the proportion of fixation time for faces. Higher Social Prioritization scores indicate more looking at faces and less looking at background objects. This task will only be completed for in-person study visits as it requires the use of a physical eye tracking device. | ClinicalTrials.gov |
| Secondary | FaceSay Efficacy: Social Deficits Improvement | Enrollment to T3 (18 weeks) | At each time point, caregivers of participants will complete the Social Responsiveness Scale, 2nd Edition (SRS- 2). The SRS-2 is a 65-item parent-report questionnaire that evaluates the frequency of reciprocal social behaviors, communication, and repetitive and stereotypic behaviors in the child. The school-age form (for ages 4-18 years) will be used. The questionnaire yields a single summary T-score that can be used as an index of the child's severity of social deficits, with higher scores indicating greater deficits. | ClinicalTrials.gov |
| Secondary | FaceSay Efficacy: Facial Expression Recognition Improvement | Enrollment to T3 (18 weeks) | At each time point, participants will be asked to complete the Victoria/Yale face processing assessment, which tests facial expression recognition skills. Overall accuracy scores (ranging from 0-100) for the facial expression recognition task will be used to quantify these skills, with higher scores reflecting better facial identity recognition. | ClinicalTrials.gov |
| Secondary | FaceSay Efficacy: Social Functioning Improvement | Enrollment to T3 (18 weeks) | At each time point, caregivers and youth will complete the Pediatric Quality of Life Inventory 4.0 (PedsQL). The PedsQL 4.0 is a 23-item measure broken down by participant age that examines physical, social, emotional, and school functioning over the past month. Scores from the social functioning sub-domain (ranging from 0-100) will be used to quantify social functioning, with higher scores indicating better social functioning. | ClinicalTrials.gov |
| Secondary | FaceSay Efficacy: Peer Relationship Improvement | Enrollment to T3 (18 weeks) | At each time point, caregivers and youth will complete the Patient Reported Outcomes Measurement Information System (PROMIS) Peer Relationships questionnaire. The PROMIS Peer Relationships questionnaire assesses the quality of the child's peer relationships. Overall T-scores for the measure will be assessed, with higher scores indicating better peer relationship quality. | ClinicalTrials.gov |
| Secondary | FaceSay Efficacy: Social Functioning Improvement | Enrollment to T3 (18 weeks) | At each time point, caregivers will complete the Childhood Behavioral Checklist (CBCL). The CBCL is a parent-report that evaluates a variety of behaviors in children including activities, school performance, and social interactions. T-scores from the social competence subdomain will be used to quantify social functioning, with higher scores reflecting better social functioning. | ClinicalTrials.gov |
| Secondary | FaceSay Efficacy: Social Information Processing | Enrollment to T3 (18 weeks) | At each time point, participants will complete the attribution and coping questionnaire which assess the child's attribution of peer's behaviors during hypothetical, ambiguous social interactions and their coping response. The percent of time the child choses each attribution and coping style will be assessed, and group differences in dominant styles will be assessed. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 16
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 9782676 | BACKGROUND | PubMed |
| 17469991 | BACKGROUND | PubMed |
| 21287255 | BACKGROUND | PubMed |
| 25382825 | BACKGROUND | PubMed |
| 25694364 | BACKGROUND | PubMed |
| 28039368 | BACKGROUND | PubMed |
| 28689249 | BACKGROUND | PubMed |
| 30091946 | BACKGROUND | PubMed |
| 30847703 | BACKGROUND | PubMed |
| 31254938 | BACKGROUND | PubMed |
| 31675094 | BACKGROUND | PubMed |
| 31925436 | BACKGROUND | PubMed |
| 31999166 | BACKGROUND | PubMed |
| 34313751 | BACKGROUND | PubMed |
| 34605383 | BACKGROUND | PubMed |
| 38470289 | BACKGROUND | PubMed |
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)